---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-000521"
form_type: "8-K"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:35:12.501470+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Chromocell presents pipeline update at Sidoti conference, plans Phase 2a for CC8464

## Summary
- Phase 1 of CC8464 completed; 6 of 159 subjects (4%) experienced a rash; FDA accepted dose-escalation plan to reduce incidence.
- Plans Phase 2a proof-of-concept in idiopathic small fiber neuropathy (~240 patients) and open-label erythromelalgia study (N=10).
- Eye pain program: developing a CC8464 eye drop; pre-clinical ophthalmologic safety studies and POC in PRK surgery patients planned.
- Sublingual programs: exclusive worldwide license from Benuvia for diclofenac, rizatriptan, ondansetron; 505(b)(2) regulatory pathway.
- Company presented at Sidoti Small Cap Conference on March 13, 2024, with CEO Frank Knuettel and CMO Eric Lang.

## SEC filing metadata
- accession: 0001753926-24-000521
- form_type: 8-K
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000175392624000521/0001753926-24-000521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000175392624000521/g084118_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-000521
- JSON: https://secwatch.observer/filing/0001753926-24-000521.json
- Plain text: https://secwatch.observer/filing/0001753926-24-000521.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.